grepafloxacin has been researched along with levofloxacin in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (22.86) | 18.2507 |
| 2000's | 21 (60.00) | 29.6817 |
| 2010's | 6 (17.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Inui, K; Okuda, M; Takami, K; Uwai, Y | 1 |
| Hashimoto, Y; Inui, KI; Yamaguchi, H; Yano, I | 1 |
| Akazawa, M; Inui, K; Okuda, M; Saito, H; Urakami, Y | 1 |
| Keserü, GM | 1 |
| Inui, K; Saito, H; Yamaguchi, H; Yano, I | 3 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Jia, L; Sun, H | 1 |
| Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
| Brillault, J; Couet, W; De Castro, WV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Bale, MJ; Erwin, ME; Jones, RN | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Hashimoto, Y; Inui, K; Ito, T; Matsuo, Y; Yano, I | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Hashimoto, Y; Inui, K; Ito, T; Masuda, S; Yano, I | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Hashimoto, Y; Inui, K; Ito, T; Yano, I | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Johnson, AP; Livermore, DM; Warner, M | 1 |
| Adachi, F; Hirota, M; Kamikawa, K; Kanegasaki, S; Nakata, K; Totsu, T; Watanabe, J | 1 |
| Ball, P | 1 |
| Evans, ME | 1 |
| Fujimoto, K; Hirota, M; Kaneki, T; Koizumi, T; Kubo, K; Ogasawara, H; Yamamoto, H; Yamazaki, Y | 1 |
| Baumann-Wilschke, I; Rücker, M; Shakibaei, M; Stahlmann, R | 1 |
| Fujimura, A; Hakamata, Y; Hirota, M; Hishikawa, S; Kobayashi, E; Miyamoto, G; Mizuta, K | 1 |
| Di Bonaventura, G; Picciani, C; Piccolomini, R; Spedicato, I | 1 |
| Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
3 review(s) available for grepafloxacin and levofloxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
New fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Respiratory Tract Infections | 1999 |
32 other study(ies) available for grepafloxacin and levofloxacin
| Article | Year |
|---|---|
Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney.
Topics: Animals; Anion Transport Proteins; Anions; Biological Transport; Carrier Proteins; Cell Membrane; Dicarboxylic Acids; Diterpenes; DNA Primers; DNA, Complementary; Female; Folic Acid; Glutarates; Kidney; Kinetics; Methotrexate; Oocytes; p-Aminohippuric Acid; Phorbol Esters; Probenecid; Rats; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Terpenes; Tetradecanoylphorbol Acetate; Xenopus laevis | 1998 |
Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Topics: Anti-Infective Agents; Biological Transport; Caco-2 Cells; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Intestinal Mucosa; Levofloxacin; Metabolic Clearance Rate; Ofloxacin; Piperazines | 2000 |
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
Topics: Alternative Splicing; Amino Acid Sequence; Base Sequence; Cations; Cell Line; Cloning, Molecular; DNA, Complementary; Genetic Variation; Humans; Kidney; Molecular Sequence Data; Organic Cation Transport Proteins; Organic Cation Transporter 2; Tetraethylammonium; Tissue Distribution; Transfection | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Topics: Acute Kidney Injury; Animals; Anti-Infective Agents; Antineoplastic Agents; Bile Ducts; Biological Availability; Blotting, Western; Caco-2 Cells; Ciprofloxacin; Cisplatin; Duodenum; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Piperazines; Rats; Rats, Wistar; Time Factors | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
Topics: Absorption; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport, Active; Cell Line; Cell Membrane Permeability; Cyclosporins; Diffusion; Drug Interactions; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Kinetics; Lipids; Lung | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control S
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ceftizoxime; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quality Control; Quinolones; Reference Values; Spiro Compounds; Thienamycins | 1994 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Anti-Infective Agents; Cyclosporine; Epithelial Cells; Fluoroquinolones; Hydrogen-Ion Concentration; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Piperazines; Quinolones; Swine | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Topics: Animals; Anti-Infective Agents; Carbon Radioisotopes; Cimetidine; Dose-Response Relationship, Drug; Fluoroquinolones; In Vitro Techniques; Kidney Cortex; Kinetics; Levofloxacin; Male; Ofloxacin; p-Aminohippuric Acid; Piperazines; Rats; Rats, Wistar; Tetraethylammonium; Tissue Distribution | 1999 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Transepithelial transport of levofloxacin in the isolated perfused rat kidney.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biological Transport; Carbon Radioisotopes; Cimetidine; Coloring Agents; Enzyme Inhibitors; Epithelial Cells; Evans Blue; Fluoroquinolones; In Vitro Techniques; Inulin; Kidney; Levofloxacin; Male; Ofloxacin; p-Aminohippuric Acid; Perfusion; Piperazines; Rats; Rats, Wistar; Tetraethylammonium; Urine | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
Topics: Anti-Infective Agents; Antitubercular Agents; Biological Transport; Cells, Cultured; Culture Media; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium; Ofloxacin; Piperazines | 2001 |
Safety of the new fluoroquinolones compared with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines | 2000 |
Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Topics: Adenosine Triphosphate; Anti-Infective Agents; Biological Transport; Caco-2 Cells; Carbon Radioisotopes; Chlorides; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Levofloxacin; Ofloxacin; Piperazines | 2001 |
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Streptococcus pneumoniae | 2001 |
Lung tissue distribution after intravenous administration of grepafloxacin: comparative study with levofloxacin.
Topics: Animals; Anti-Infective Agents; Epithelium; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Lung; Lymph; Molecular Structure; Ofloxacin; Piperazines; Pulmonary Circulation; Sheep; Time Factors | 2002 |
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Availability; Cyclosporine; Enzyme Inhibitors; Fluoroquinolones; Genes, MDR; Intestinal Mucosa; Kidney; Levofloxacin; Liver; Male; Mice; Mice, Knockout; Ofloxacin; Piperazines; Rats; Tissue Distribution | 2002 |
Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Infective Agents; Calcium; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Limb Buds; Magnesium; Male; Mice; Mice, Inbred Strains; Ofloxacin; Piperazines; Pregnancy; Quinolones | 2002 |
Fluoroquinolone concentrations in plasma, urine, and bile after oral administration in rats with renal failure: useful technique for long-term bile collection.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bile; Blood Urea Nitrogen; Fluoroquinolones; Levofloxacin; Male; Ofloxacin; Osmolar Concentration; Piperazines; Rats; Rats, Wistar; Reference Values; Renal Insufficiency; Specimen Handling | 2001 |
E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach.
Topics: Anemia; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cost-Benefit Analysis; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Hematologic Neoplasms; Humans; Levofloxacin; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections | 2004 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |